TP53 and B-cell chronic lymphocytic leukemia: In B-CLL, the FCR regimen (fludarabine, cyclophosphamide, rituximab) continues to represent the ‘standard of care’, and an existing weight of evidence demonstrates a survival advantage for FCR over historical approaches, at least for younger patients (<65 years) without TP53 aberrations [30].